research use only

Eflornithine (DFMO) hydrochloride hydrate Decarboxylase inhibitor

Cat.No.S4582

Eflornithine (DFMO) hydrochloride hydrate inhibits polyamine biosynthesis by the selective, irreversible inhibition of ornithine decarboxylase (ODC). A chemoprotective agent that blocks angiogenesis. Its biological half-life is 8 hours.
Eflornithine (DFMO) hydrochloride hydrate Decarboxylase inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 236.64

Quality Control

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
J774.1 Antitrypanosomal assay 48 hrs Antitrypanosomal activity against Trypanosoma brucei brucei TC221 infected in mouse J774.1 cells after 48 hrs by alamar blue assay, IC50 = 22.9 μM. 22376072
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight 236.64 Formula

C6H12F2N2O2.HCl.H2O

Storage (From the date of receipt)
CAS No. 96020-91-6 Download SDF Storage of Stock Solutions

Synonyms Difluoromethylornithine hydrochloride hydrate, MDL-71782 hydrochloride hydrate, RMI-71782 hydrochloride hydrate, α-difluoromethylornithine hydrochloride hydrate Smiles C(CC(C(F)F)(C(=O)O)N)CN.O.Cl

Solubility

In vitro
Batch:

Water : 47 mg/mL

DMSO : Insoluble ( Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Orn decarboxylase [2]
In vitro

When cultured cells are treated with α-difluoromethyl-Orn, an inhibitor of polyamine biosynthesis, production of hydrogen peroxide is suppressed and programmed cell death did not occur[1].

In vivo

Eflornithine alters changes in vascular responsiveness associated with coarctation hypertension

References

Applications

Methods Biomarkers Images PMID
Western blot c-Myc / α-tubulin S4582-WB-1 25248858
Growth inhibition assay 2T1 cells S4582-Growth-inhibition-assay-1 21093499
IHC H&E staining of pancreas p21 / PCNA S4582-IHC-1 25248858
IHC/IF ODC expression in pancreatic tumors Cav-1 / β-catenin S4582-IHC-IF-1 25248858

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05594563 Recruiting
Type 1 Diabetes
Emily K. Sims|Juvenile Diabetes Research Foundation|Cancer Prevention Pharmaceuticals Inc.|Indiana University
March 14 2023 Phase 2
NCT05500508 Recruiting
Cancer|Solid Tumor|Solid Carcinoma|Advanced Cancer|DIPG Brain Tumor|Ovary Cancer|Breast Cancer|Papillary Thyroid Cancer|Head and Neck Cancer|Gastric Cancer|Nsclc|Mesotheliomas Pleural|Mesothelioma Peritoneum|Esophageal Cancer|Diffuse Midline Glioma H3 K27M-Mutant|Endometrial Cancer|Cervical Cancer|Melanoma|Colorectal Cancer|Glioma Malignant
Aminex Therapeutics Inc.
November 29 2022 Phase 1|Phase 2
NCT04696029 Recruiting
Medulloblastoma
Giselle Sholler|Milton S. Hershey Medical Center
March 29 2021 Phase 2
NCT03536728 Completed
Cancer|Solid Tumor|Solid Carcinoma|Advanced Cancer
Aminex Therapeutics Inc.
June 12 2018 Phase 1
NCT02636569 Active not recruiting
Non-melanoma Skin Cancer
University of Alabama at Birmingham
October 25 2017 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.